| pubmed-article:9371897 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C0149931 | lld:lifeskim |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C0528166 | lld:lifeskim |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C0520010 | lld:lifeskim |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C0681815 | lld:lifeskim |
| pubmed-article:9371897 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:9371897 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:9371897 | pubmed:dateCreated | 1997-12-8 | lld:pubmed |
| pubmed-article:9371897 | pubmed:abstractText | Previous studies demonstrated that zolmitriptan at doses of 1 to 25 mg was highly effective in treating acute migraine attacks. The 2.5-mg dose had a favorable therapeutic effect with high efficacy and good tolerability. The objective of this study was to further evaluate the efficacy of a single 2.5-mg dose of zolmitriptan (Zomig, formerly known as 311C90) for acute treatment of a single moderate or severe migraine attack. The study was a randomized, double-blind, placebo-controlled clinical trial. Female and male patients, 12 to 65 years old, with migraine (with or without aura) for > or = 1 year, one to six migraines per month, and age at onset < 50 years were included; 327 patients were screened and randomized to receive either zolmitriptan (n = 219) or placebo (n = 108). Patients treated a single moderate or severe migraine headache with 2.5 mg zolmitriptan or placebo and recorded clinical efficacy and adverse events on a diary form. Headache response at 2 hours was 62% for zolmitriptan compared with 36% for placebo (p < 0.001); at 4 hours, headache response was 70% with zolmitriptan and 37% with placebo (p < 0.001). Headache recurrence in patients treated with 2.5 mg zolmitriptan was 22% (versus placebo 30%). The headache response at 4 hours, pain-free rate, and response rate of nonheadache symptoms favored zolmitriptan over placebo. No serious adverse events were associated with zolmitriptan treatment. A 2.5-mg dose of zolmitriptan is clinically effective and well tolerated for the acute treatment of migraine. | lld:pubmed |
| pubmed-article:9371897 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9371897 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:9371897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9371897 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9371897 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:9371897 | pubmed:issn | 0028-3878 | lld:pubmed |
| pubmed-article:9371897 | pubmed:author | pubmed-author:CadyR KRK | lld:pubmed |
| pubmed-article:9371897 | pubmed:author | pubmed-author:SaperJ RJR | lld:pubmed |
| pubmed-article:9371897 | pubmed:author | pubmed-author:KlapperJ AJA | lld:pubmed |
| pubmed-article:9371897 | pubmed:author | pubmed-author:RamadanN MNM | lld:pubmed |
| pubmed-article:9371897 | pubmed:author | pubmed-author:EarlN LNL | lld:pubmed |
| pubmed-article:9371897 | pubmed:author | pubmed-author:SolomonG DGD | lld:pubmed |
| pubmed-article:9371897 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9371897 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:9371897 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9371897 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9371897 | pubmed:pagination | 1219-25 | lld:pubmed |
| pubmed-article:9371897 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:meshHeading | pubmed-meshheading:9371897-... | lld:pubmed |
| pubmed-article:9371897 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9371897 | pubmed:articleTitle | Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. | lld:pubmed |
| pubmed-article:9371897 | pubmed:affiliation | Cleveland Clinic Foundation, OH, USA. | lld:pubmed |
| pubmed-article:9371897 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9371897 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9371897 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:9371897 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9371897 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9371897 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9371897 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9371897 | lld:pubmed |
